Bloomberg is reporting that Russia's President Vladimir Putin has said that his country registered the first coronavirus vaccine. Several weeks ago, other publications suggested that members of the Russian elite received an experimental COVID-19 immunization.
Putin has added that Russia expected to begin mass production of the vaccine developed by the Gamaleya Institute in Moscow, in the near future. The long-serving president added that his daughter was recently vaccinated. Rodrigo Duterte, President of the Philippines, said he is volunteering to take the vaccine.
The Russian rouble is strengthening in response, with USD/RUB falling below 73.
Various academic institutions and pharmaceutical firms are engaging in efforts to develop immunization for the disease that is gripping the world. Moderna, Novavax, the University of Oxford, and many other companies are in the race.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.